卡泊芬净治疗恶性血液病患者化疗或移植过程中肺真菌感染临床研究

目的研究卡泊芬净（Caspofungin）治疗恶性血液病患者化疗或移植过程中肺真菌感染的疗效及安全性。方法回顾性分析卡泊芬净治疗恶性血液病肺真菌感染患者的疗效和不良反应。结果20例疗效评价病例中，临床有效率为80％（16／20）。其中1例痊愈，13例显效，2例进步，4例用药之后无效。低钾血症（13／20）、低钙血症（11／20）、低蛋白血症（9／20），转氨酶、尿素、胆红素、碱性磷酸酶及转肽酶等指标升高为主要不良反应。结论卡泊芬净是治疗恶性血液病患者化疗或移植过程中肺真菌感染有效的药物，其不良反应可以耐受。

Treatment of lung fungal infection with caspofungin in patients with malignant hemopathy after chemotherapy or during stem cell transplantation

Objective To study the efficacy and safety of caspofungin on lung fungal infection in patients with malignant hemopathy after chemotherapy or during stern cell transplantation. Methods Efficiency and adverse effects of caspofungin on lung fungal infection in patients with malignant hemopathy were retrospectively analyzed. Results The total effective rate of caspofungin for lung fungal infection was 80%（16/20）. Among the 20 cases, completely recovery was achieved in 1, excellent improvement in 13, improvement in 2, and response to caspofungin treatment in 4, respectively. The main adverse effects of caspofungin were elevated hypopotassaemia（13/20）, hypocalcemia（11/20）, hypoproteinemia（9/20）, transaminase, urea, hiliruhin, ALP, and r-GT. Conclusion Caspofungin is very effective against lung fungal infection in patients with maliant hemopathy after chemotherapy or during stem cell transplantation with tolerable side-effects.